FDA Approval of Keytruda® in Head and Neck Cancer Highlights Potential for Gedeptin® Combination Therapy
The FDA's approval of Keytruda® for head and neck cancer treatment underscores the therapeutic potential of combining it with GeoVax’s Gedeptin®, aiming to enhance tumor clearance and reduce relapse rates.
